Nearly half of children with obesity who received family-based behavioral treatment (FBT) alongside an enhanced standard of care in a primary care setting achieved a clinically meaningful weight reduction, according to results of the TEAM UP randomized trial published in JAMA Pediatrics
The finding is significant for pharmacists because it establishes that an intensive behavioral intervention long confined to specialty research clinics can be delivered—and billed to Medicaid and private insurance—in the pediatrician’s office, giving the medication conversation a durable behavioral foundation rather than a substitute.1,2
What the Trial Tested
The Treatment Efforts Addressing Child Weight Management by Unifying Patients, Parents, and Providers (TEAM UP) trial was a pragmatic, comparative-effectiveness study conducted from 2019 to 2024 across 41 primary care practices in Louisiana, New York, Missouri, and Illinois
Investigators randomized 730 children aged 6 to 15 years with obesity to enhanced standard of care (ESOC) alone or ESOC plus FBT. ESOC was led by the primary care practitioner and intensified based on a child’s response; the FBT arm added up to 33 sessions with a trained interventionist—typically a registered dietitian or behavioral health provider—attended by the child and a parent. Both interventions ran 12 months, with follow-up at 18 months.1,2
FBT coaches families to monitor eating, activity, and weight; set goals; modify the home environment; and use positive reinforcement and parental modeling to sustain behavior change.1,2
The Weight and Quality-of-Life Results
Both groups started roughly 77% above a healthy weight. At 12 months, children in the FBT arm reduced percent median body mass index (BMI) by −6.4 units (95% CI, −8.29 to −4.43) versus −2.6 units (95% CI, −4.46 to −0.71) for ESOC alone—a between-group difference of −3.8 units (95% CI, −6.20 to −1.34; P = .002) that persisted through 18 months. About 42% of the FBT group met the threshold for clinically meaningful weight reduction, roughly 1.5 times the rate in the ESOC group. Weight-related quality of life also improved more in the FBT arm. No adverse events were deemed related to trial participation.1,2
Why the Delivery Model Matters
Roughly half of participating families were covered by Medicaid, and about 1 in 5 reported food insecurity—populations typically underrepresented in behavioral obesity research. The trial also enrolled children with common comorbidities such as attention-deficit/hyperactivity disorder or anxiety who are usually excluded. Because much of the study ran during the COVID-19 pandemic, more than 75% of FBT sessions were delivered by telehealth, with outcomes comparable to in-person care.2
Families attended about 17 sessions on average—fewer than offered—yet still benefited, and the intent-to-treat design means the results may understate the effect at fuller attendance.2
The Context for Pharmacists
The intervention exemplifies the intensive health behavior and lifestyle treatment that the American Academy of Pediatrics’ 2023 clinical practice guideline names as the foundation of pediatric obesity care, recommending referral for children aged 6 years and older. Childhood obesity affects approximately 1 in 5 US children and adolescents, or about 14.7 million youths. As GLP-1 receptor agonists reshape obesity treatment, the investigators note FBT can be used alone or alongside medication—a point relevant for pharmacists counseling families weighing pharmacotherapy against, or in addition to, behavioral approaches.3,4
